Conditions: Conjunctivitis, Allergic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 157
Healthy volunteers: no

Brief summary:
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.

Detailed description:

Arms:
arm 1: One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0. arm 2: One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0. arm 3: One drop of Placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Interventions: intervention 1: Alcaftadine 0.25% intervention 2: Olopatadine 0.2% intervention 3: dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
Intervention descriptions: intervention 1: One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0. intervention 2: One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0. intervention 3: One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.

Protocol document: